Please login to the form below

Not currently logged in
Email:
Password:

Dr Reddy's Laboratories

This page shows the latest Dr Reddy's Laboratories news and features for those working in and with pharma, biotech and healthcare.

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval

The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories. ... Reddy’s generic earlier this month.

Latest news

  • Indivior slumps as patent dispute rises US generic spectre Indivior slumps as patent dispute rises US generic spectre

    Indivior said it plans to appeal the decision, which held that three US patents on Suboxone were valid but that a generic from Indian drugmaker Dr Reddy's Laboratories drug does ... He said that Dr Reddy's has not yet been granted FDA approval for its

  • Fresenius Kabi buys Akorn and Merck's biosimilar businesses Fresenius Kabi buys Akorn and Merck's biosimilar businesses

    Adding in Merck's biosimilars business takes it right back into the biotech sphere. ... Merck kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories at a time when the company was facing patent expiries on some

  • Merck confirms sale of biosimilar division Merck confirms sale of biosimilar division

    The German group kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories, at a time when the company was facing patent expiries on ... At the time the Dr Reddy's deal was announced the biosimilars market was a

  • Dr Reddy's brings its generics portfolio to France Dr Reddy's brings its generics portfolio to France

    Continues the European roll-out of its oncology and anti-infective products. Dr Reddy's Laboratories will next month launch its generics portfolio in France as it continues to expand its ... Our business expansion in Europe is testimony to Dr Reddy's

  • Dr. Reddy’s enters €118m product agreement with UCB in India Dr. Reddys enters €118m product agreement with UCB in India

    Portfolio acquisition will expand firm’s therapy footprint. Dr. Reddy's Laboratories has entered a 118m (INR 800 Crores) definitive agreement to acquire a select portfolio of established products from UCB ... Reddy's' therapy footprint in the areas of

More from news
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    The three deals with Mayne Pharma, Impax Laboratories and Dr Reddy's, for a combined value of over $1.5bn, cover portfolios of marketed and approved generic drugs, drugs currently pending ... acquisition assets/ return of rights. 586. Teva and Allergan/

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • MedImmune appoints Dr Anand Subramony MedImmune appoints Dr Anand Subramony

    While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group. ... Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson &Johnson/Alza

  • New global head of HR for Dr Reddy’s New global head of HR for Dr Reddys

    Sripada Chandrasekhar joins from IBM. Hyderabad, India-headquartered Dr Reddy's Laboratories has appointed a former IBM executive president and global head of human resources. ... Chakraborty remains with Dr Reddy's, and has retained all but the HR

  • Dr Reddy’s appoints Umang Vohra to lead US business Dr Reddys appoints Umang Vohra to lead US business

    Will be replaced as chief financial officer by Saumen Chakraborty. Indian generics company Dr Reddy's Laboratories has appointed Umang Vohra as the new head of its North American business. ... He first joined the company in 2002, moving from Pepsico-India

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics